La Jolla Pharmaceutical (NASDAQ:LJPC) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
This table compares La Jolla Pharmaceutical and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|La Jolla Pharmaceutical||-1,324.04%||-337.55%||-80.07%|
This is a summary of recent ratings for La Jolla Pharmaceutical and Titan Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|La Jolla Pharmaceutical||0||2||4||0||2.67|
La Jolla Pharmaceutical currently has a consensus price target of $16.40, indicating a potential upside of 75.59%. Titan Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 214.96%. Given Titan Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Titan Pharmaceuticals is more favorable than La Jolla Pharmaceutical.
Risk and Volatility
La Jolla Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Institutional and Insider Ownership
93.9% of La Jolla Pharmaceutical shares are held by institutional investors. Comparatively, 5.1% of Titan Pharmaceuticals shares are held by institutional investors. 25.3% of La Jolla Pharmaceutical shares are held by company insiders. Comparatively, 6.5% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares La Jolla Pharmaceutical and Titan Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|La Jolla Pharmaceutical||$10.06 million||25.16||-$199.47 million||($7.85)||-1.19|
|Titan Pharmaceuticals||$6.62 million||2.59||-$9.02 million||($0.79)||-1.61|
Titan Pharmaceuticals has lower revenue, but higher earnings than La Jolla Pharmaceutical. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than La Jolla Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
La Jolla Pharmaceutical beats Titan Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.